What is Zymeworks's zanidatamab — R&D?

Zymeworks (ZYME) reported zanidatamab — R&D of $623K in Q1 2026.

What does zanidatamab — R&D mean?

This metric represents the total organizational effort and resource allocation dedicated to the advancement of the zanidatamab clinical program. It encompasses the strategic focus on clinical trials, regulatory filings, and scientific development activities specific to this bispecific antibody candidate. Tracking this allows investors to assess the company's commitment to its primary pipeline asset and the progression of its clinical development lifecycle.

Zymeworks ZYME Zanidatamab — R&D

Other product segments

Expense for other preclinical and research programs

$6.37M+226%

ZW191

$2.85M-2.7%

ZW220

$2.14M+439%

ZW251

$2.03M+1,085%

ZW171

$1.83M-31.5%

Similar metrics at other companies

NRIXZelebrudomide (NX-2127) — R&D

$1.91M+72.3%

AXSMAZD7325 — Research And Development Expense

$2.3M—

NUVLZidesamtinib — Direct Expenses Related To Program

$12.31M-20.8%

SRRKApitegromab — Research And Development Expense

$20.26M+5.0%

IDYADarovasertib — External Clinical Development Expenses

$23.33M+1.4%

ADMAADMA Bio Manufacturing — Research And Development Expense

$2.6M+214%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's zanidatamab — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's zanidatamab — R&D?: Zymeworks (ZYME) reported zanidatamab — R&D of $623K in Q1 2026.
What does zanidatamab — R&D mean?: This metric represents the total organizational effort and resource allocation dedicated to the advancement of the zanidatamab clinical program. It encompasses the strategic focus on clinical trials, regulatory filings, and scientific development activities specific to this bispecific antibody candidate. Tracking this allows investors to assess the company's commitment to its primary pipeline asset and the progression of its clinical development lifecycle.